Pharmalot By Ed Silverman Pharmalittle: Pfizer to merge off-patent business with Mylan; conservatives try to sabotage Trump pricing plan
Pharmalot By Ed Silverman Pharmalittle: Glaxo is set to hire a new chairman; Gilead tries to bulk up with new deal
Pharmalot By Ed Silverman Once-a-day pills for combating HIV are a better deal than some people think
Pharmalot By Ed Silverman Gilead’s HIV prevention pill can greatly reduce new infections in targeted rollouts
Health By Erin Mershon Insurer’s mailing to customers made HIV status visible through envelope window
In the Lab By Shayla Love Genetic fossil-hunters dig through HIV’s long history for clues to new treatments
In the Lab By Andrew Joseph A drug used to treat Crohn’s disease could suppress HIV, monkey study suggests
Heavyweights By Rebecca Robbins The drug pricing crusader at the center of one of the nastiest fights of the election season
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Glaxo believes its plan for HIV treatment is a ‘game changer’
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Another analysis finds new cholesterol drugs are not cost-effective
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Gilead’s preventive HIV pill must be covered in England
First Opinion By Peter Piot and Mitchell Warren Prevention must be at the forefront to meet global HIV goals
First Opinion By Anthony S. Fauci and Deborah L. Birx An AIDS-free world is possible, but do we have the will to achieve it?